Thu, Aug 21, 2014, 12:12 PM EDT - U.S. Markets close in 3 hrs 48 mins


% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

btimnextmicrosoft 180 posts  |  Last Activity: 52 minutes ago Member since: Oct 15, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • btimnextmicrosoft by btimnextmicrosoft 52 minutes ago Flag

    MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three of whom are independent.

    Andy Arno, 55, has 30 years of experience working with emerging growth companies. He is currently Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., a family investment group. He was previously President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He was also Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of the parent company, Merriman Holdings, Inc.

    Nat Ricciardi, 65, spent his entire 39-year biopharmaceutical career at Pfizer Inc., retiring in 2011 as a member of the Pfizer Executive Leadership Team after holding the positions of President, Pfizer Global Manufacturing, and Senior Vice President of Pfizer Inc. In addition to his corporate leadership role, he was directly responsible for all of Pfizer's internal and external supply organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products......

  • Huge milestones that will get us up another notch!

    Sentiment: Strong Buy

  • btimnextmicrosoft by btimnextmicrosoft Aug 14, 2014 2:11 PM Flag

    tick, tick, tick

  • btimnextmicrosoft by btimnextmicrosoft Aug 12, 2014 8:31 PM Flag

    Monday-Revs up 19%
    Tuesday: FDA approval for one of many ECM/hydrogel products:
    BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device. Premvia™ is the first FDA-cleared member of BioTime’s HyStem® family of hydrogels, which are designed to mimic the natural structures of the human body’s extracellular matrix. According to the FDA clearance, the product is indicated for the management of wounds including: partial thickness, full-thickness, tunneling wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, donor skin graft sites, post-Moh’s surgery, post-laser surgery, podiatric wounds, wound dehiscence, abrasions, lacerations, second degree burns, skin tears and draining wounds.
    The global market for aesthetic and reconstructive surgery was estimated to exceed $6 billion annually and is composed of many distinct market segments. Premvia™ is expected to serve a subset of these segments. “We plan to rapidly complete the review and implementation of the requisite quality and manufacturing documentation in advance of introducing the product to the market. Additionally the Company will undertake selected clinical studies to further refine the target market niches, and following that, will lay our final plans for associated marketing initiatives and strategies,” said William Tew, Ph.D., BioTime’s Chief Commercial Officer. “HyStem®-based products such as Premvia™ and Renevia™ (the latter anticipated to begin its pivotal clinical trial in Europe later this year) are anticipated to provide the company with opportunities for significant near-term revenue, while balancing the long-term opportunities created by the Company’s pluripotent stem cell technology platform, which provides the potential for the industrial-scale manufacture of all of the cellular components of the human body.

  • Reply to

    BTX going back over highs of $10 in 2015

    by btimnextmicrosoft Aug 12, 2014 2:32 PM
    btimnextmicrosoft btimnextmicrosoft Aug 12, 2014 6:54 PM Flag

    Exactly! Cancer and stem cell therapeutics quietly making progress. Will go main stream in a few years.
    Today as you know one of our regen devices received first round FDA approval. Next up AST and UCLA to announce stroke regen therapy to start clinical trials.

    Sentiment: Strong Buy

  • Reply to

    BTX going back over highs of $10 in 2015

    by btimnextmicrosoft Aug 12, 2014 2:32 PM
    btimnextmicrosoft btimnextmicrosoft Aug 12, 2014 3:47 PM Flag

    -Nano-peptide cancer diagnostics....nothing on the market, competitors Merck, J&J
    -Stem cell/ECM regen therapies....nothing on the market, competitors all behind.
    BTX clear leader in the world with 800+stem patents

    Sentiment: Strong Buy

  • btimnextmicrosoft by btimnextmicrosoft Aug 12, 2014 2:32 PM Flag

    Get on the bus !

  • btimnextmicrosoft by btimnextmicrosoft Aug 12, 2014 1:57 PM Flag

    See you at $12 next year!

  • btimnextmicrosoft by btimnextmicrosoft Aug 11, 2014 5:43 PM Flag

    Good sign, LifeMap research products starting to roll!

  • Reply to

    News Tues?

    by btimnextmicrosoft Aug 11, 2014 2:18 PM
    btimnextmicrosoft btimnextmicrosoft Aug 11, 2014 4:49 PM Flag

    Great post heads! Amazing products starting to line up, breast/bladder/lung cancer diagnostics, cosmetic surgery device, array of stem cell regen. Very impressive next gen. Best biz plan, A+ stem cell sector choice.

  • btimnextmicrosoft by btimnextmicrosoft Aug 11, 2014 2:18 PM Flag

    Movin up slow and steady on low volume like we did from $0.4-$10, the move back up past 5 yr highs has begun.

  • Reply to

    A radical idea

    by sunburst_mt Aug 10, 2014 11:38 AM
    btimnextmicrosoft btimnextmicrosoft Aug 10, 2014 3:09 PM Flag

    Sell something??? Yeah that's radical, uh not selling my shares, maybe in 6 mo when we are over $12.

    Sentiment: Strong Buy

  • btimnextmicrosoft by btimnextmicrosoft Aug 8, 2014 2:05 PM Flag

    major news Tuesday can move us into 2nd gear

  • btimnextmicrosoft btimnextmicrosoft Aug 8, 2014 1:57 PM Flag

    Long termer baby!

  • All in!

  • btimnextmicrosoft by btimnextmicrosoft Aug 7, 2014 1:01 PM Flag


  • CYTX is basically a small innovator of medical hardware and their time is up. CYTX market cap reflects their revs, which are more then BTX's.....but CYTX is a one shot deal that is currently getting leaped frogged by a slew of hardware companies with major capital. Yes they have a patented adipose cocktail but it just failed in clinical trial.
    Then there is BTX which has been moving slowly over the years to build scientifically cutting edge, sound products based on the foundation of basic stem cell biology. There have been times where i was worried they were spreading themselves too thin. But Dr. West has stuck to his guns with hESC's and not only proven himself to be a great scientist and business man but more importantly a true visionary. Anyone with long term shares in this company are very smart.
    Market cap will explode by years end as their cancer diagnostics start to hit the market along with multiple regen trials that are fully paid for. So again, the smoke is settling in this sector and BTX is the 800 lb Gorilla with 600+ patents, 7 subsidiaries, no debt, cancer diagnostics backed by major hospitals.....and the list goes on and on.

  • Reply to

    AST 1st update

    by drwestclone Jul 29, 2014 5:27 PM
    btimnextmicrosoft btimnextmicrosoft Aug 5, 2014 5:45 PM Flag

    opc-1 already went through years of safety testing. All went well. ACTC is getting great results from their hESC retina cells. Fast track will happen, right wing embryo scare tactics are old news.

  • btimnextmicrosoft by btimnextmicrosoft Aug 5, 2014 5:36 PM Flag

    Been about 20 years since the start of the stem cell sector. Lots of companies have either sold assets or failed. Cytori looks to be finished. BTX more like the 800lb gorilla of stem cells.

    Sentiment: Strong Buy

  • btimnextmicrosoft by btimnextmicrosoft Aug 1, 2014 6:14 PM Flag

    By end of 2015 Biotimes MIL $ cancer diagnostic profits will start to come in and their dendritic cancer therapy will be in clinical trials. Here is one of our key patents:

    Identification of Human Embryonic Progenitor Cell Targeting Peptides Using Phage DisplayAbstract
    Human pluripotent stem (hPS) cells are capable of differentiation into derivatives of all three primary embryonic germ layers and can self-renew indefinitely. They therefore offer a potentially scalable source of replacement cells to treat a variety of degenerative diseases. The ability to reprogram adult cells to induced pluripotent stem (iPS) cells has now enabled the possibility of patient-specific hPS cells as a source of cells for disease modeling, drug discovery, and potentially, cell replacement therapies. While reprogramming technology has dramatically increased the availability of normal and diseased hPS cell lines for basic research, a major bottleneck is the critical unmet need for more efficient methods of deriving well-defined cell populations from hPS cells. Phage display is a powerful method for selecting affinity ligands that could be used for identifying and potentially purifying a variety of cell types derived from hPS cells.

0.0013+0.0001(+8.33%)11:30 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.